Cargando…

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen

We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Versluijs, A. Birgitta, de Koning, Coco C. H., Lankester, Arjan C., Nierkens, Stefan, Kollen, Wouter J., Bresters, Dorine, Lindemans, Caroline A., Boelens, Jaap Jan, Bierings, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941455/ https://www.ncbi.nlm.nih.gov/pubmed/34781362 http://dx.doi.org/10.1182/bloodadvances.2021005224

Ejemplares similares

Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients
por: Nijstad, A. Laura, et al.
Publicado: (2021)

Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
por: Shin, Ho Cheol, et al.
Publicado: (2012)

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
por: Andersson, Borje S., et al.
Publicado: (2022)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Respiratory Virus (RV) from Broncho Alveolar Lavage (BAL) Prior to Hematopoietic Cell Transplantation (HCT): A Strong Predictor for Allo-Immune Mediated Lung Syndromes (allo-LS)
por: Versluys, Birgitta, et al.
Publicado: (2015)

Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients
por: Troullioud Lucas, Alexandre G., et al.
Publicado: (2023)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT
por: Shouval, Roni, et al.
Publicado: (2022)

Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors
por: Bashey, Asad, et al.
Publicado: (2023)

Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG
por: Turki, Amin T., et al.
Publicado: (2021)

CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia
por: Akahoshi, Yu, et al.
Publicado: (2023)

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT
por: Geerlinks, Ashley V., et al.
Publicado: (2023)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation
por: Nunez, Lina, et al.
Publicado: (2022)

Recognizing a Non-classical Telomeropathy before Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Case Series
por: Nederlof, Iris, et al.
Publicado: (2019)

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
por: Menghrajani, Kamal, et al.
Publicado: (2022)

Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS
por: Chevallier, Patrice, et al.
Publicado: (2016)

Emergence of human CMV-induced NKG2C(+) NK cells is associated with CD8(+) T-cell recovery after allogeneic HCT
por: van der Ploeg, Kattria, et al.
Publicado: (2023)

Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy
por: Chiesa, Robert, et al.
Publicado: (2022)

Targeted busulfan and fludarabine-based conditioning for bone marrow transplantation in chronic granulomatous disease
por: Ju, Hee Young, et al.
Publicado: (2016)

Infection with a respiratory virus before hematopoietic cell transplantation is associated with alloimmune-mediated lung syndromes
por: Versluys, Birgitta, et al.
Publicado: (2018)

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
por: Dekker, Linde, et al.
Publicado: (2022)

What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?
por: AlJohani, Naif I., et al.
Publicado: (2021)

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
por: Langenhorst, Jurgen B., et al.
Publicado: (2018)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Reconstitution of T Cell Subsets Following Allogeneic Hematopoietic Cell Transplantation
por: Dekker, Linde, et al.
Publicado: (2020)

Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage
por: He, Xin, et al.
Publicado: (2016)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation
por: Langenhorst, Jurgen B., et al.
Publicado: (2020)

Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study
por: Achini-Gutzwiller, Federica R., et al.
Publicado: (2023)

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
por: Andersson, Borje S., et al.
Publicado: (2016)

Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective
por: Beerepoot, Shanice, et al.
Publicado: (2019)

Naive T Cells in Graft Versus Host Disease and Graft Versus Leukemia: Innocent or Guilty?
por: Dekker, Linde, et al.
Publicado: (2022)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
por: Bug, Gesine, et al.
Publicado: (2023)

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

The role of respiratory viruses in developing bronchiolitis obliterans and IPS in pediatric HCT patients
por: Rossen, J.W.A., et al.
Publicado: (2006)

Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation
por: Garcia-Perez, Laura, et al.
Publicado: (2021)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vh7necano7nukf8v4fbnhpjn5t